JCO;颠覆!新的研究表明输精管切除术与前列腺癌风险增加无关

2016-09-20 MedSci MedSci原创

两项美国大型队列研究显示,男性行输精管切除术并没有增加其前列腺癌发生及因前列腺癌死亡的风险。 既往一项前瞻性研究认为行输精管切除术后患前列腺癌的风险增加10%,发生高级别及致命前列腺癌的风险极高,但是其他研究则认为二者并没有联系。 该项新的研究发表于Journal of Clinical Oncology,纳入了参与癌症预防研究Ⅱ的年龄超过40岁的363726位男性,观察输精管切除术和

两项美国大型队列研究显示,男性行输精管切除术并没有增加其前列腺癌发生及因前列腺癌死亡的风险。

既往一项前瞻性研究认为行输精管切除术后患前列腺癌的风险增加10%,发生高级别及致命前列腺癌的风险极高,但是其他研究则认为二者并没有联系。

该项新的研究发表于Journal of Clinical Oncology,纳入了参与癌症预防研究Ⅱ的年龄超过40岁的363726位男性,观察输精管切除术和前列腺癌致死之间的联系。1982-2012年间的随访中共有7451人死于前列腺癌。

结果显示,输精管切除术与前列腺癌死亡率无关:42015名行输精管切除术的男性中,641人死于前列腺癌,相比之下,321711名未行输精管切除术的男性中, 6810人死于前列腺癌[危险比为1.01,(95%可信区间为0.93-1.10)]。

第二个队列研究纳入了参加大型癌症预防试验的营养亚研究的66542名男性,观察,探究输精管切除术是否与前列腺癌的发生率或死亡率有关。其中10589名男性做过输精管切除术,1992-2011年间9133名男性诊断为前列腺癌。
研究人员发现,输精管切除术和总的前列腺癌发病率 (1.02 (0.96 to 1.08)) 或高危级别前列腺癌的发生率 (0.91 (0.78 - 1.07)格里森评分 >8)无关。
该研究的第一作者Eric Jacobs,来自格鲁吉亚亚特兰大美国癌症协会流行病学研究项目,认为“尽管既往研究认为二者之间有关,但我们的结果显示输尿管切除术与前列腺癌发生风险或前列腺癌死亡无关,这或许能够给予考虑行输精管切除术的男性一些安慰”。他还补充道,这是迄今为止验证这个问题的最大研究。

最后他建议,“担心致命性前列腺癌发生的男性应着重关注保持健康的体重,吸烟者应戒烟.肥胖和吸烟都是致命性前列腺癌发生的高危因素,且与其他多种疾病的发生相关”.

原始出处:

Susan Mayor. Vasectomy is not linked to raised risk of prostate cancer, study finds. BMJ 2016; 354 doi: http://dx.doi.org/10.1136/bmj.i5080

Jacobs EJ, Anderson RL, Stevens VL, et al. Vasectomy and prostate cancer incidence and mortality in a large US cohort. J Clin Oncol2016. doi:10.1200/JCO.2015.66.2361.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
    2016-11-02 sjq027
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
    2017-07-05 lidong40
  6. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
    2016-09-22 泌尿内切罗

    总结的很棒,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
    2016-09-22 lhl629

    谢谢分享,继续学习。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1981662, encodeId=bd5c19816621f, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Thu Jan 12 15:07:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876826, encodeId=7d8518e682610, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 28 04:07:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735324, encodeId=540e1e3532457, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Fri Feb 10 00:07:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061567, encodeId=736f206156ee6, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Nov 02 13:07:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891307, encodeId=f6cc189130ee9, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Jul 05 03:07:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022552, encodeId=47d520225521e, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Sun Oct 09 06:07:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132927, encodeId=23e913292e7d, content=总结的很棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230819/6c8b6deecf0c4462997dba3e904a7948/3c0084692c8b437b9c620bc9a2e97b95.jpg, createdBy=e6011937142, createdName=泌尿内切罗, createdTime=Thu Sep 22 12:00:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132881, encodeId=c42413288186, content=谢谢分享,继续学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ceb079804, createdName=lhl629, createdTime=Thu Sep 22 09:58:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132330, encodeId=86ca13233051, content=无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Wed Sep 21 12:21:00 CST 2016, time=2016-09-21, status=1, ipAttribution=)]
    2016-09-21 zibozhouping

    无论是国际还是国内都是目前肿瘤免疫治疗的研究热点!!总结的很好!!

    0

相关资讯

JCO:输精管切除术与前列腺癌有关?

在线发表于《临床肿瘤学杂志》(JCO)的一项队列研究显示,对于接受了输精管切除术的男性人群,前列腺癌风险将出现增加。该研究共纳入超过50,000个样本。总体而言,输精管切除术与前列腺癌风险增加10%有关,与高度恶性和致死性前列腺癌风险增加20%有关。常规接受PSA筛查的男性群体,该风险甚至增加50%。研究的主要作者,来自哈佛大学公共卫生学院的Lorelei A. Mucci, ScD强调,前列腺癌